Researchers launch large study to track HER2+ breast cancer survival
NCT ID NCT06603597
First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This observational study will follow 1000 people with HER2-positive breast cancer to see how patient and tumor characteristics relate to outcomes like survival and treatment response. Participants are not given any new treatment—researchers simply collect data over time. The goal is to improve understanding of what influences long-term results in this type of breast cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2024
- Expected to finish
-
Oct 2044
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with stage I-IV HER2-positive breast cancer.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Stage I-IV HER2-positive breast cancer Exclusion Criteria: * None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 + breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
KUCC - Briarcliff
ACTIVE_NOT_RECRUITINGWestwood, Kansas, 66205, United States
-
KUCC - Indian Creek
ACTIVE_NOT_RECRUITINGOverland Park, Kansas, 66211, United States
-
KUCC - Lee's Summit
ACTIVE_NOT_RECRUITINGLee's Summit, Missouri, 64064, United States
-
KUCC - Olathe
ACTIVE_NOT_RECRUITINGWestwood, Kansas, 66205, United States
-
KUCC - Overland Park
ACTIVE_NOT_RECRUITINGOverland Park, Kansas, 66215, United States
-
The University of Kansas Cancer Center
RECRUITINGWestwood, Kansas, 66205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new antibody boost treatment for Hard-to-Treat HER2 breast cancer?
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can an oral chemo pill boost breast cancer treatment?
- Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?
- Blood test may reveal if breast cancer treatment is working
- New vaccine combo aims to supercharge immune attack on breast cancer